Kindred Biosciences Announces Two New Appointments to Board of Directors
News provided by
Share this article
Share this article
SAN FRANCISCO, Feb. 9, 2021 /PRNewswire/ Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor, and Nanxi Liu, CEO and Co-Founder of Enplug and Co-Founder of Nanoly Bioscience, to its Board of Directors, effective February 5, 2021. We are very pleased to welcome Lyndon and Nanxi to our Board, said Chief Executive Officer, Richard Chin, M.D. With extensive investing, operating, and business development experience, Lyndon will bring valuable additional perspectives to KindredBio. Nanxi is a seasoned entrepreneur recognized by Forbes and Fortune magazines, who brings management and public board experience to KindredBio. We look forward to working with them as we advance our in